The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of an COCH associated condition.

A composition having nanoparticles having lipids; a polysaccharide coating, an active agent and iron oxide. The active agent can be ciprofloxacin or fluocinolone. A method of treatment of ear disease or ear infection including the administration of a pharmaceutical formulation comprising nanoparticles and magnetically pushing or pulling the nanoparticles to a treatment site.

A composition having nanoparticles having lipids; a polysaccharide coating, an active agent and iron oxide. The active agent can be ciprofloxacin or fluocinolone. A method of treatment of ear disease or ear infection including the administration of a pharmaceutical formulation comprising nanoparticles and magnetically pushing or pulling the nanoparticles to a treatment site.

This application relates to a pharmaceutical composition for anti-inflammation, including a probiotic and an antibiotic, and a method of preventing or treating inflammation by using the same. In one aspect, the method includes locally administrating a probiotic and an antibiotic to an inflamed area of a subject.

This application relates to a pharmaceutical composition for anti-inflammation, including a probiotic and an antibiotic, and a method of preventing or treating inflammation by using the same. In one aspect, the method includes locally administrating a probiotic and an antibiotic to an inflamed area of a subject.

Methods for introducing a gene into a cell of the inner ear, e.g., a cochlear or vestibular cell, e.g., a hair cell, e.g., for therapy, that include the use of exosomes associated with one or more adeno-associated viral (AAV) particles.

The present disclosure relates to methods of targeting specific cell types within the cochlea using optimized gene therapy vectors. In particular, the disclosure provides gene therapy vectors to specifically target cochlear cells and methods of treating hearing impairment and hearing-loss related disorders.

The present disclosure relates to methods of targeting specific cell types within the cochlea using optimized gene therapy vectors. In particular, the disclosure provides gene therapy vectors to specifically target cochlear cells and methods of treating hearing impairment and hearing-loss related disorders.

Provided herein are compositions and methods for treating and preventing hearing loss, for treating and preventing a disorder associated with loss, damage, or absence of sensory auditory hair cells, and/or for improving auditory function in a subject in need thereof. Also provided are compositions and methods for the generation of auditory hair cells that allow perception of stimuli in a subject in need thereof.

Provided herein are compositions and methods for treating and preventing hearing loss, for treating and preventing a disorder associated with loss, damage, or absence of sensory auditory hair cells, and/or for improving auditory function in a subject in need thereof. Also provided are compositions and methods for the generation of auditory hair cells that allow perception of stimuli in a subject in need thereof.